Vivos TherapeuticsVVOS +9.34%41 EBIT per Share is $-1.93 as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Vivos Therapeutics ranks better than 91.88% on this metric.
Vivos Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.45.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.93.
During the past 3 years, the average EBIT per Share Growth Rate was 58.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 41.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vivos Therapeutics's EBIT per Share or its related term are showing as below:
VVOS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.8 Med: 5.7 Max: 58.5
Current: 58.5
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Vivos Therapeutics was 58.50% per year. The lowest was -24.80% per year. And the median was 5.70% per year.
VVOS's 3-Year EBIT Growth Rate is ranked better than 91.88% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs VVOS: 58.50
Vivos Therapeutics (NAS:VVOS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vivos Therapeutics EBIT per Share Related Terms
Vivos Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos Therapeutics (VVOS) has a EBIT per Share of $-1.93 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #56 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 8.1%.
Is Vivos Therapeutics' EBIT per Share too high?
Vivos Therapeutics' current EBIT per Share is $-1.93. Based on the distribution chart, Vivos Therapeutics ranks #56 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' EBIT per Share compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #56 out of 690 companies for EBIT per Share. This places Vivos Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current EBIT per Share is $-1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.49 — trading 57.5% below its estimated fair value. The current EBIT per Share is $-1.93. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current EBIT per Share is $-1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.49 is trading 57.5% below its estimated GF Value™ of $1.16.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
EBIT per Share: $-1.93
GF Value™: $1.16 vs. price of $0.49 (57.5% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
